» Articles » PMID: 20101723

Amyloid-beta Oligomers: Possible Roles As Key Neurotoxins in Alzheimer's Disease

Overview
Journal Mt Sinai J Med
Specialty General Medicine
Date 2010 Jan 27
PMID 20101723
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease is the most common form of senile dementia. Although the amyloid-beta peptide was identified in 1984 as the major constituent of the senile plaques that characterize the disease, accumulating evidence indicates that the plaque density does not correspond well to the concurrent disease state. In order to resolve this disconnect, a number of recent studies have shifted away from the senile plaque and classical fibrillar forms of amyloid toward a less well structured species as the proximate neurotoxic factor underlying cognitive failure in Alzheimer's disease: soluble amyloid-beta peptide oligomer (also known as the amyloid-beta peptide-derived diffusible ligand). Paradoxically, several studies in the last 2 years have shown that picomolar levels of amyloid-beta peptide have neutral activity or perhaps even an essential role in learning and memory. Here we highlight some of the key observations underlying the growing focus on the amyloid-beta peptide oligomer.

Citing Articles

Emerging Alzheimer's disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions.

Tobeh N, Bruce K Front Aging Neurosci. 2023; 15:1259012.

PMID: 38020773 PMC: 10630922. DOI: 10.3389/fnagi.2023.1259012.


Intermediate Antiparallel β Structure in Amyloid β Plaques Revealed by Infrared Spectroscopic Imaging.

Holcombe B, Foes A, Banerjee S, Yeh K, Wang S, Bhargava R ACS Chem Neurosci. 2023; 14(20):3794-3803.

PMID: 37800883 PMC: 10662787. DOI: 10.1021/acschemneuro.3c00400.


Spin state dependent peroxidase activity of heme bound amyloid β peptides relevant to Alzheimer's disease.

Nath A, Roy M, Dey C, Dey A, Dey S Chem Sci. 2022; 13(48):14305-14319.

PMID: 36545147 PMC: 9749105. DOI: 10.1039/d2sc05008k.


Synthetic, Cell-Derived, Brain-Derived, and Recombinant β-Amyloid: Modelling Alzheimer's Disease for Research and Drug Development.

Varshavskaya K, Mitkevich V, Makarov A, Barykin E Int J Mol Sci. 2022; 23(23).

PMID: 36499362 PMC: 9738609. DOI: 10.3390/ijms232315036.


An in vitro workflow of neuron-laden agarose-laminin hydrogel for studying small molecule-induced amyloidogenic condition.

Namchaiw P, Bunreangsri P, Eiamcharoen P, Eiamboonsert S, Poo-Arporn R PLoS One. 2022; 17(8):e0273458.

PMID: 36026506 PMC: 9416999. DOI: 10.1371/journal.pone.0273458.


References
1.
Haass C . Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 2004; 23(3):483-8. PMC: 1271800. DOI: 10.1038/sj.emboj.7600061. View

2.
Selkoe D . Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008; 192(1):106-13. PMC: 2601528. DOI: 10.1016/j.bbr.2008.02.016. View

3.
Bernstein S, Dupuis N, Lazo N, Wyttenbach T, Condron M, Bitan G . Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem. 2010; 1(4):326-31. PMC: 2918915. DOI: 10.1038/nchem.247. View

4.
Haass C, Selkoe D . Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007; 8(2):101-12. DOI: 10.1038/nrm2101. View

5.
Murray M, Bernstein S, Nyugen V, Condron M, Teplow D, Bowers M . Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization. J Am Chem Soc. 2009; 131(18):6316-7. PMC: 2697393. DOI: 10.1021/ja8092604. View